Frank Rimerman Advisors LLC Has $374,000 Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Frank Rimerman Advisors LLC increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 349.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,152 shares of the company’s stock after buying an additional 2,451 shares during the period. Frank Rimerman Advisors LLC’s holdings in Moderna were worth $374,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in MRNA. Profund Advisors LLC lifted its holdings in Moderna by 20.9% during the 2nd quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock worth $6,676,000 after buying an additional 9,719 shares in the last quarter. Summit Trail Advisors LLC lifted its stake in shares of Moderna by 12.8% during the second quarter. Summit Trail Advisors LLC now owns 3,558 shares of the company’s stock valued at $423,000 after acquiring an additional 403 shares during the period. Pacer Advisors Inc. boosted its holdings in Moderna by 9.5% in the second quarter. Pacer Advisors Inc. now owns 45,298 shares of the company’s stock valued at $5,379,000 after acquiring an additional 3,930 shares during the last quarter. Skandinaviska Enskilda Banken AB publ increased its position in Moderna by 0.3% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 245,687 shares of the company’s stock worth $29,150,000 after purchasing an additional 706 shares during the period. Finally, Benjamin F. Edwards & Company Inc. increased its position in Moderna by 297.2% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 5,343 shares of the company’s stock worth $634,000 after purchasing an additional 3,998 shares during the period. Institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 689 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total transaction of $81,467.36. Following the completion of the transaction, the chief financial officer now owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO James M. Mock sold 689 shares of the business’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the sale, the chief financial officer now owns 7,269 shares of the company’s stock, valued at $859,486.56. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The disclosure for this sale can be found here. In the last quarter, insiders have sold 78,158 shares of company stock valued at $9,259,012. 15.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MRNA. Barclays reduced their target price on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating on the stock in a research note on Monday, September 16th. Piper Sandler reduced their price objective on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, September 13th. JPMorgan Chase & Co. cut shares of Moderna from a “neutral” rating to an “underweight” rating and dropped their target price for the company from $88.00 to $70.00 in a research report on Friday, September 13th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Friday, September 13th. Finally, Leerink Partners dropped their price objective on Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and an average price target of $100.44.

Moderna Trading Down 0.3 %

Shares of NASDAQ:MRNA opened at $63.94 on Wednesday. The firm has a market cap of $24.50 billion, a price-to-earnings ratio of -4.08 and a beta of 1.67. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $170.47. The company’s fifty day simple moving average is $87.70 and its 200 day simple moving average is $110.43. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.47) by $0.14. The firm had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The company’s revenue for the quarter was down 29.9% on a year-over-year basis. During the same quarter last year, the business posted ($3.62) EPS. As a group, research analysts forecast that Moderna, Inc. will post -9.52 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.